| Acne Vulgaris
Absorica vs Arazlo
Side-by-side clinical, coverage, and cost comparison for acne vulgaris.Deep comparison between: Absorica Ld vs Arazlo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsArazlo has a higher rate of injection site reactions vs Absorica Ld based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Arazlo but not Absorica Ld, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Absorica Ld
Arazlo
At A Glance
Oral
Twice daily
Retinoid
Topical
Daily
Retinoid
Indications
- Acne Vulgaris
- Acne Vulgaris
Dosing
Acne Vulgaris ABSORICA: 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks (up to 2 mg/kg/day for severe disease with scarring or trunk involvement); ABSORICA LD: 0.4 to 0.8 mg/kg/day in two divided doses for 15 to 20 weeks (up to 1.6 mg/kg/day for severe disease).
Acne Vulgaris Apply a thin layer to affected areas once daily; avoid eyes, mouth, paranasal creases, and mucous membranes; not for oral, ophthalmic, or intravaginal use.
Contraindications
- Pregnancy
- Hypersensitivity to isotretinoin, Vitamin A (given chemical similarity), or any component of the product
- Pregnancy (may cause fetal harm)
Adverse Reactions
Most common Cheilitis, hypertriglyceridemia, dry skin, dry lips, fatigue, headache, epistaxis, arthralgia, back pain, musculoskeletal pain
Serious Embryo-fetal toxicity, psychiatric disorders (including suicidal ideation, depression, psychosis), intracranial hypertension, serious skin reactions, pancreatitis, hepatotoxicity, inflammatory bowel disease, musculoskeletal abnormalities, hearing impairment, hypersensitivity reactions
Most common (>=1%) Application site pain, application site dryness, application site exfoliation, application site erythema, application site pruritus
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Pharmacology
Isotretinoin is a retinoid that inhibits sebaceous gland function and keratinization; clinical improvement in nodular acne is associated with a reduction in sebum secretion, reflecting reduced sebaceous gland size and inhibition of sebaceous gland differentiation.
Tazarotene is a retinoid prodrug converted by deesterification to tazarotenic acid, which binds to retinoic acid receptors RARalpha, RARbeta, and RARgamma with relative selectivity for RARbeta and RARgamma, potentially modifying gene expression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Absorica Ld
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Arazlo
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Absorica Ld
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Arazlo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Absorica Ld
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Arazlo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Absorica Ld.
No savings programs available for Arazlo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Absorica LdView full Absorica Ld profile
ArazloView full Arazlo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.